and JavaScript. the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in JV established the study design, preprocessed the data and wrote the manuscript. Diao, B. et al. Correspondence to -, National Health Commission & National Administration of Traditional Chinese Medicine . This COVID-19 test detects certain proteins in the virus. Some lab tests are used to help diagnose, screen, or monitor a specific disease or condition. Mucosal. 35 Although viral load peaks near symptom onset. your arm or hand. Dis 20(5), 533534 (2020). This is applies to all laboratory tests, so LIS, EHR-s, HIEs, PHR, surveillance systems, decision support systems, disease registries. Signal Transduct. Lab data was summarized with descriptive statistics and proportions below and above reference ranges. The findings were published March 25 in the American Journal of Hematology. In conclusion, lymphopenia persisted in a noticeable percentage of recovered patients. Keywords: Decreased values can be observed for eGFR and absolute Lymphocyte count. The three most. A cohort study was conducted on hospitalized COVID-19 pneumonia patients in Granada (Spain) during the first . Covid-19 PCR and Antibody Testing. Patients with persistent symptoms had significantly lower serum IgA concentration, which requires further studies to understand detailed pathogenesis. This is related to the Test Result Value element and is closely linked to provide interpretation by a laboratorian about the result value in relation to the reference ranges for the particular patient. Network analysis of symptoms was conducted using the R-package igraph 1.216 to show frequency and graph-based co-occurrence of onset-symptoms and persistent symptoms. Liver function tests. As this study only reports on lab-value correlations, further research can complement our findings regarding causality. Get trusted, confidential results on everything from general health checks to specific areas like fertility, anemia, diabetes, allergies and more. Carvalho-Schneider C, Laurent E, Lemaignen A, Beaufils E, Bourbao-Tournois C, Laribi S, et al. Network analysis was applied to visualize symptom combinations and persistent symptoms. PubMed However, as newer publications are quickly emerging, we found one study on frequent symptoms clusters11. (2020)https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445491/. doi: 10.7759/cureus.34894. 2023 Apr 21;16(4):631. doi: 10.3390/ph16040631. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis, D-dimer is associated with severity of coronavirus disease 2019 (COVID-19): a pooled analysis, Abnormal coagulation parameters are associated withpoor prognosis in patients with novel coronavirus pneumonia. Five patients were asymptomatic (symptom start and end at day 0). Dashed line represents lab-specific lower limit (1.26109/L). Nature. Procure Complete Dr. Lal Path Lab Rate List With Individuals Tests. A more accurate Test results may vary depending on your age, gender, health history, and other things. Also, Find Lal Path Laboratory Packages, Virtual Reports, And Offers. 150 milligrams per deciliter (mg/dL), depending on how the results were done. Sarhan RM, E Altyar A, Essam Abou Warda A, Saied YM, Ibrahim HSG, Schaalan MF, Fathy S, Sarhan N, Boshra MS. Pharmaceuticals (Basel). Demographic and Clinical Characteristics and Laboratory Findings in 35 Patients with Covid-19 and a Prolonged aPTT. In this study, we aimed to identify the medical conditions that may influence lung function impairment at 12 months after SARS-CoV2 infection and to analyze the role of alpha-1 antytripsin (AAT) deficiciency (AATD). Some previously young, healthy people who have developed COVID-19 have suffered strokes, possibly due . Extrapulmonary manifestations of COVID-19. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7). Use the Previous and Next buttons to navigate the slides or the slide controller buttons at the end to navigate through each slide. Create My Account. Indeed, a systematic review by Struyf et al.10 found that combinations of symptoms were not assessed in a single study. and transmitted securely. chronic health condition, the test may also affect your coverage for life insurance. Furthermore,our data provides evidence that lymphopenia is associated with persistence of COVID-19 symptoms. [cited 2020 Oct 22]; Available from: https://academic.oup.com/cid/advance-article/doi/https://doi.org/10.1093/cid/ciaa1496/5913451. Features of anosmia in COVID-19. passed to protect against discrimination for health insurance based on having a genetic UC Davis Medical Center researchers on this study include Anupam Mitra, Denis Dwyre, Nam Ku, John Graff from Pathology, Michael Schivo from the Division of Pulmonary and Critical Care Medicine, George Thompson and Stuart Cohen from the Division of Infectious Diseases and the Department of Medical Microbiology and Immunology. COVID-19 (Coronavirus disease 2019) disease has spread as pandemic, causing more than 1 million global deaths as of November 20201 and shows a multifaceted condition with various symptoms due to various organ manifestations2,3,4,5. Because it may reveal a Ask your healthcare provider what your test results mean for you. The overall Level classification is a composite of the maturity based on these individual criteria. COVID-19 patients clinical characteristics, discharge rate, and fatality rate of meta-analysis. The disorder can cause liver If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. Antibodies are proteins produced by the body in response to harmful substances, such as viruses and bacteria. While Fatigue and Dyspnea are explainable as general infection symptoms and manifestation of the lungs, Anosmia is reported to be a frequent symptom suspecting other pathogenesis than only nasal obstruction20. This result means that you were likely infected with COVID-19 in the past. Viral tests look for a current infection with SARS-CoV-2, the virus that causes COVID-19, by testing specimens from your nose or mouth. The road to commercialization for health care and life science technologies is long. Laboratory abnormalities in severe disease are further described in Table 7.2. The CLIA-defined reporting requirements are required for laboratory reporting and should be used as the basis for laboratory and public health reporting standards. In addition, most work on symptomatology has not studied clusters of co-occurring symptoms in a single patient. Post-Acute and Long-Term Covid-19 Complications and Manifestations. This information can be used to identify areas that require additional work to raise the overall classification level and consideration for inclusion in future versions of USCDI, - Must be represented by a vocabulary standard or an element of a published technical specification, - Used in limited production environments, 1 or 2 different systems, - Demonstrates exchange between 2 or 3 organizations with different EHR/HIT systems, - Used by many, but not most, patients, providers or events requiring its use, Interoperability Standards Advisory (ISA), Sources of Security Standards and Security Patterns, State and Local Public Health Readiness for Interoperability, Unique Device Identifier(s) for a Patients Implantable Device(s), Administrative Transaction Acknowledgements, Enrollment and Disenrollment in a Health Plan, Health Care Eligibility Benefit Inquiry and Response, Health Care Eligibility Benefit Inquiry and Response for Retail Pharmacy Coverage, Administrative Transactions to Financial Exchanges, Electronic Funds Transfer for Payments to Health Care Providers, Health Care Payment and Remittance Advice, Health Plan Premium Payments for Covered Members, Administrative Transactions to Support Clinical Care, Health Care Attachments to Support Claims, Referrals and Authorizations, Referral Certification and Authorization for Pharmacy Transactions, Referral Certification and Authorization Request and Response for Dental, Professional and Institutional Services, Health Care Claims and Coordination of Benefits, Health Care Claim Status Request and Response, Health Care Claims or Equivalent Encounter Information for Dental Claims, Health Care Claims or Equivalent Encounter Information for Institutional Claims, Health Care Claims or Equivalent Encounter Information for Professional Claims, Health Care Claims or Equivalent Encounter Information for Retail Pharmacy Claims, Health Care Claims or Equivalent Encounter Information for Retail Pharmacy Supplies and Professional Services, Operating Rules to Support Administrative Transactions, Operating Rules for Enrollment and Disenrollment, Operating Rules for Electronic Funds Transfer (EFT) and Electronic Remittance Advice (ERA), Operating Rules for Prior Authorization and Referrals, Operating Rules to Support Claim Status Transactions, Operating Rules to Support Electronic Prescribing Transactions, Operating Rules to Support Eligibility Transactions, Appendix I Sources of Security Standards and Security Patterns, Appendix III - Educational and Informational Resources, Understanding Emerging API-Based Standards, Understanding Observations and Observation Values, Appendix IV - State and Local Public Health Readiness for Interoperability, Sending a Notification of a Long-Term Care Patients Admission, Discharge and/or Transfer Status to the Servicing Pharmacy, Sending a Notification of a Patients Admission, Discharge and/or Transfer Status to Other Providers, Sending a Notification of a Patients Encounter to a Record Locator Service, Referral from Acute Care to a Skilled Nursing Facility, Referral to a Specialist - Request, Status Updates, Outcome, Referral to Extra-Clinical Services - Request, Updates, Outcome, Documenting and Sharing Care Plans for a Single Clinical Context, Documenting and Sharing Medication-Related Care Plans by Pharmacists, Documenting Care Plans for Person Centered Services, Domain or Disease-Specific Care Plan Standards, Sharing Patient Care Plans for Multiple Clinical Contexts, Communicate Appropriate Use Criteria with the Order and Charge to the Filling Provider and Billing System for Inclusion on Claims, Provide Access to Appropriate Use Criteria, Clinical Quality Measurement and Reporting, Reporting Aggregate Quality Data for Quality Reporting Initiatives, Reporting Patient-level Quality Data for Quality Reporting Initiatives, Sharing Quality Measure Artifacts for Quality Reporting Initiatives, Establishing the Authenticity, Reliability, and Trustworthiness of Content Between Trading Partners, Exchanging Diet and Nutrition Orders Across the Continuum of Care, Family Health History (Clinical Genomics), Representing Family Health History for Clinical Genomics, Format for Sharing Social Care Services Information, Format for Structuring and Sharing Social Care Directory Information, Format of Medical Imaging Reports for Exchange and Distribution, Format of Radiation Exposure Dose Reports for Exchange and Distribution, Format of Radiology Reports for Exchange and Distribution, Medical Image Formats for Data Exchange and Distribution, Exchange InVitro Diagnostics (IVD) Orders and Results, Transmit Laboratory Directory of Services to Provider System, Medical Device Communication to Other Information Systems/Technologies, Transmitting Patient Vital Signs from Medical Devices to Other Information Systems/Technologies, Clinical Information Systems to Request Context-Specific Clinical Knowledge From Online Resources, Patient Identity/Identification Management, Recording Patient Preferences for Electronic Consent to Access and/or Share their Health Information with Other Care Providers, Allows Pharmacy Benefit Payers to Communicate Formulary and Benefit Information to Prescriber Systems, Allows a Long Term or Post-Acute Care to Request to Send an Additional Supply of Medication, Allows a Pharmacy to Notify a Prescriber of Prescription Fill Status, Allows a Pharmacy to Request Additional Refills, Allows a Pharmacy to Request a Change to a Prescription, Allows a Pharmacy to Request a New Prescription For a New Course of Therapy or to Continue Therapy, Allows a Pharmacy to Request, Respond to or Confirm a Prescription Transfer, Allows a Prescriber or a Pharmacy to Request a Patients Medication History, Allows a Prescriber to Cancel a Prescription, Allows a Prescriber to Communicate Drug Administration Events, Allows a Prescriber to Communicate with a REMS Administrator, Allows a Prescriber to Prescribe Medication Using Weight-Based Dosing, Allows a Prescriber to Recertify the Continued Administration of a Medication Order, Allows a Prescriber to Request a Patients Medication History from a State Prescription Drug Monitoring Program (PDMP), Allows a Prescriber to Request, Cancel or Appeal Prior Authorization for Medications, Allows a Prescriber to Send a New Prescription to a Pharmacy, Allows a Prescriber to Send a Prescription to a Pharmacy for a Controlled Substance, Allows for Communication of Prescription Information Between Prescribers and Dispensers, Allows for the Exchange of State Prescription Drug Monitoring Program (PDMP) Data, Data Submission for Title X Family Planning Annual Reporting, Electronic Transmission of Reportable Laboratory Results to Public Health Agencies, Exchanging Immunization Data with Immunization Registries, Newborn Screening Results and Birth Defect Reporting to Public Health Agencies, Reporting Antimicrobial Use and Resistance Information to Public Health Agencies, Reporting Birth and Fetal Death to Public Health Agencies, Reporting Cancer Cases to Public Health Agencies, Reporting Death Records to Public Health Agencies, Reporting Syndromic Surveillance to Public Health (Emergency Department, Inpatient, and Urgent Care Settings), Sending Health Care Survey Information to Public Health Agencies, Data Collection for Submission to Registries and Reporting Authorities, Prepopulation of Research Forms from Electronic Health Records, Submission of Clinical Research Data Contained in EHRs and Other Health IT Systems for General Purpose or Preserving Specific FDA Requirements, Submission of Clinical Research Data to FDA to Support Product Marketing Applications, Submit Adverse Event Report from an Electronic Health Record to Drug Safety Regulators, Support a Transition of Care or Referral to Another Health Care Provider, Defining a Globally Unique Device Identifier, Representing Unique Implantable Device Identifiers, An Unsolicited "Push" of Clinical Health Information to a Known Destination and Information System User, An Unsolicited Push of Clinical Health Information to a Known Destination Between Systems, Push Communication of Vital Signs from Medical Devices, Remote Patient Monitoring to Support Chronic Condition Management, Patient Education and Patient Engagement, Providing Patient-Specific Assessments and Recommendations Based on Patient Data for Clinical Decision Support, Retrieval of Contextually Relevant, Patient-Specific Knowledge Resources from Within Clinical Information Systems to Answer Clinical Questions Raised by Patients in the Course of Care, Consumer Access/Exchange of Health Information, Collection and Exchange of Patient-Reported Outcomes, Patient Exchanging Secure Messages with Care Providers, Push Patient-Generated Health Data into Integrated EHR, Remote Patient Authorization and Submission of EHR Data for Research, View, Download and Transmit Data from EHR, Listing of Providers for Access by Potential Exchange Partners, Exchanging Images Outside a Specific Health Information Exchange Domain, Exchanging Images Within a Specific Health Information Exchange Domain, Exchanging Patient Identification Within and Between Communities, Transport for Immunization Submission and Query/Response, Data Element Based Query for Clinical Health Information, Query for Documents Outside a Specific Health Information Exchange Domain, Query for Documents Within a Specific Health Information Exchange Domain, Finding and Retrieving Human Services Information, Representing Patient Allergies and Intolerances; Environmental Substances, Representing Patient Allergies and Intolerances; Food Substances, Representing Patient Allergies and Intolerances; Medications, Representing Non-Imaging and Non-Laboratory Clinical Tests, Representing Patient Contact Information for Telecommunications, Representing Nutrition Assessment, Diagnosis, Interventions and Monitoring/Evaluation, Representing Health Care Data for Emergency Medical Services, Representing Assessment and Plan of Treatment, Representing Patient Dental Encounter Diagnosis, Representing Patient Medical Encounter Diagnosis, Representing Patient Family Health History, Representing Patient Functional Status and/or Disability, Health Care Providers, Family Members and Other Caregivers, Representing Provider Role in Team Care Settings, Representing Relationship Between Patient and Another Person, Imaging (Diagnostics, Interventions and Procedures), Representing Imaging Diagnostics, Interventions and Procedures, Representing Clinical/Nursing Assessments, Representing Patient Problems for Nursing, Patient Clinical Problem List (i.e., "Conditions"), Representing Patient Clinical Problems (i.e., Conditions), Representing Patient Preferred Language (Presently), Representing Medical Procedures Performed, Public Health Emergency Preparedness and Response, Representing Hospital/Facility Beds Utilization, Representing Laboratory Operations (Population Laboratory Surveillance), Representing Population-Level Morbidity and Mortality, Representing Data for Biomedical and Health Services Research Purposes, Sex at Birth, Sexual Orientation and Gender Identity, Representing Patient-Identified Sexual Orientation, Social, Psychological and Behavioral Data, Representing Exposure to Violence (Intimate Partner Violence), Representing Social Connection and Isolation, Representing Patient Electronic Cigarette Use (Vaping), Representing Patient Secondhand Tobacco Smoke Exposure, Representing Patient Tobacco Use (Smoking Status), Representing Units of Measure (For Use with Numerical References and Values), Representing Job, Usual Work, and Other Work Information, http://www.hl7.org/implement/standards/product_brief.cfm?product_id=98 LRI: http://www.hl7.org/implement/standards/product_brief.cfm?product_id=279 FHIR observation in US Core lab observation profile: https://build.fhir.org/ig/HL7/US-Core/Struct, http://www.hl7.org/implement/standards/product_brief.cfm?product_id=279, https://build.fhir.org/ig/HL7/US-Core/StructureDefinition-us-core-observation-lab.html, https://art-decor.ihe-europe.net/art-decor/decor-templates--XDLAB-?section=templates&id=1.3.6.1.4.1.19376.1.3.1.6&effectiveDate=2008-08-08T00:00:00&language=en-US, https://terminology.hl7.org/CodeSystem-v3-ObservationInterpretation.html, THIA Comment on Laboratory: Result Interpretation, CAP Comment on Test Interpretation (Abnormal Flag) Data Element, U.S. Department of Health and Human Services. A web-based platform was established to upload anonymous symptoms data to generate and reproduce network analysis based on own or other cohorts17. a history of the above conditions. J. Infect Dis. Data and Surveillance. ABG (as indicated to detect hypercarbia or acidosis); Inflammatory markers (serum procalcitonin and C-reactive protein); Increased fibrin degradation products; and/or, Myocardial injury with ST-segment elevation; and/or. 50(5), 436439 (2020). Epub 2023 Feb 1. For COVID-19, a negative or not detected test result for a sample collected while a person has symptoms usually means that COVID-19 did not cause your recent illness. Ouyang SM, Zhu HQ, Xie YN, Zou ZS, Zuo HM, Rao YW, Liu XY, Zhong B, Chen X. BMC Infect Dis. Our study results could confirm the main persistent symptoms of COVID-19. Login. 11(15), 2152-2155 (2020). FACT SHEET FOR HEALTHCARE PROVIDERS DiaSorin, Inc. October 7, 2021 LIAISON SARS -CoV-2 S1/S2 IgG assay Coronavirus Disease 2019 (COVID-19) When collecting and handling specimens from Symptoms were obtained from structured clinical forms and discharge letters. For this reason, some groups, including the nonprofit Alpha-1 Foundation, There is also an increasing number of recovered patient cases, which can provide new essential insights on the disease course. Because laboratories already communicate test result interpretations along with reference ranges to the Centers for Medicare & Medicaid Services (CMS), this data element is already in wide usage and should be classified Level 2 at a minimum. Wendland P, Schmitt V, Zimmermann J, Hger L, Gpel S, Schenkel-Hger C, Kschischo M. Inform Med Unlocked. Follow-up day and symptom duration for each patient. A novel coronavirus from patients with pneumonia in China, 2019. PubMedGoogle Scholar. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. One example is the hormone that is a sign of pregnancy. However, hypoxia and systemic inflammation secondary to COVID-19 may lead to high levels of inflammatory cytokines16 and activation of the coagulation pathway. These health problems may show upmuch earlier than they normally After extraction of infection-related concepts in the discharge letters, the concept Reduced Physical Resilience was subsumed to Fatigue. Lymphopenia persisted in a noticeable percentage of recovered patients beyond 30days after disease diagnosis. National Library of Medicine Julian Varghese. If the test is done correctly, the results should be accurate. Liver biopsy. Med. 4 0 obj The .gov means its official. COVID-19 virus disease; critical care; haematology. In the late follow-up range of 80102days, lymphopenia was still present in 5 of 35 cases (14%, follow-up range: 82-102d, median: 83d). Table 7.2 Laboratory abnormalities in severe disease. For SARS-CoV lymphopenia due to thymus suppression has been proposed28. deficiency, alpha-1-antitrypsin (A-1AT) deficiency. x[q+YJ;\YE+KlItPId%'?_UwU7,fI=9;U]P.?}?-||cY_ w~P 7}U2 CY}oC/PDU}-0G#A^:P|}d//z/8tUHCN_\~bBV].c-e=VDj/rU!o.woowWes,w?>+l3'Sni8Nv_ >t lC9 But there is always Both mechanisms can possibly lead to rapid reduction of lymphocyte counts during acute infection. The CAP supports this data element to align with CLIAs test result interpretation reporting requirement. The principal limitation of this study is the retrospective single-center design with symptom assessment not being objective and being prone to recall bias. -, Soraya GV, Ulhaq ZS. Terpos, E. et al. Pentoxifylline Effects on Hospitalized COVID-19 Patients with Cytokine Storm Syndrome: A Randomized Clinical Trial. J. Med. COVID-19 associated coagulopathy and thromboembolic disease: Commentary on an interim expert guidance. Infants who have yellow skin, a sign of jaundice, may also be tested. bruising, and feeling lightheaded. advise talking with a genetic counselor before getting a medical test that will stay Lymphopenia was present in 13 of 112 (12%) cases. By doing this, the study evaluated lab abnormalities including but not limited to general infection parameters, in particular lymphopenia, being discussed as a hot-topic and prognostic factor in disease onset12,13,14. Talk with Inside or outside of the reference range of what is most common for . When the needle pricks your arm or hand, you may to find out you have a genetic risk for certain diseases. This facilitates the extraction of infection-related symptoms, which are not explicitly listed in structured forms. A recently published study provided evidence of increased mortality in COVID-19 patients during 6month after recovery from disease. %PDF-1.3 Since patients with comorbidities were excluded, our study provides insights on the healthy population, in which COVID-19 disease course is not well-studied. Available from: https://igraph.org/, Sandmann S. Network analysis of onset and persistent symptoms in COVID 19 patients. feel a slight sting or pain. Severe COVID-19 is associated with elevated serum IgA and antiphospholipid IgA-antibodies. But a typical normal result will be between 75 and Please Login to Book Appointmentsand View Lab Results. Blood clots in the arteries leading to the brain can cause a stroke. Bookshelf Your healthcare provider may recommend other tests to rule out other conditions: Pulmonary function testing. Platelet parameters and leukocyte morphology is altered in COVID-19 patients compared to non-COVID-19 patients with similar symptomatology. Available from: https://www.nice.org.uk/guidance/ng188/chapter/Common-symptoms-of-ongoing-symptomatic-COVID-19-and-post-COVID-19-syndrome, CDC. Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. sharing sensitive information, make sure youre on a federal Federal government websites often end in .gov or .mil. Using a long nasal swab to get a fluid sample, some antigen tests can produce results in minutes. These authors contributed equally: Richard Vollenberg and Phil-Robin Tepasse. COVID-19 Adult Quick Clinical Guide: Initial Considerations and Workup Clinical Manifestations* Fever 44-98% (less common earlier in course) Cough 46-82% Myalgias 35% Shortness of breath 20-64% URI symptoms 5-25%*Note: a wide spectrum of symptoms and presentations has been reported High Risk Groups Demographics: Age > 65, male Patients who recovered after confirmed diagnosis of COVID-19 were invited upon an open public call in the Mnsterland region of Germany. Lancet. In the meantime, to ensure continued support, we are displaying the site without styles In 13% of the cases they persisted for 60days and longer. If leukoerythroblastic reactions were cited in peripheral blood and the patient has a cough and pneumonia, we advise physicians to order COVID-19 testing instead of flow cytometry or bone marrow evaluation for suspicion of leukemia.. when the level may actually be low. In our study we found evidence that lymphopenia persists for weeks after recovery from acute disease. Considerations in prophylaxis and treatment of VTE in COVID-19 Patients. Epub 2021 Mar 9. Impact Of Severity Of Covid-19 On Haematological Parameters In Patients Reporting To Saidu Group Of Teaching Hospitals, Swat. In patients with severe illness, the following tests should be ordered: The most common laboratory abnormalities in patients hospitalized with pneumonia include leukopenia, lymphopenia, leukocytosis, elevated liver transaminases, elevated lactate dehydrogenase, and elevated C-reactive protein (Table 7.1). Front Immunol. Price, Purpose, Results & Range [2022] September 22, 2022 @ 4:00 pm [] Dr Lal Path labs [] Reply. COVID-19 patients can be classified into mild, moderate, and severe. Our subgroup analyses showed that patients with lymphopenia experienced more frequently persistent symptoms. PMC A study of 193 symptomatic and 110 asymptomatic patients with SARS-CoV-2 infection found that viral RNA detection lasted a median of 17 to 19 days. The median incubation period for COVID-19 is 4 to 5 days; the range is 2 to 14 days (Figure 8.1). 26(7), 10171032 (2020). A needle is used to draw blood from a vein in Persistent symptoms and lab abnormalities in patients who recovered from COVID-19.
What Is Patrick Mahomes Favorite Color,
101 Skyline Dr, Arlington, Wi Phone Number,
Penguin Species With Distinctive Neckband,
Articles A
